GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3049% above fair value
$47.29−3.73 (-7.31%)
Close on Nov 17, 2026Market cap $1.41BP/E –Yield –
GeneDx price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
GeneDx's price to sales ratio was 3.6× on Nov 10, 2026, against 12.0× a year earlier. Over the last 5 years it ranged from 0.0× to 12.0×, with a median of 3.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 3.6× | −5.7 |
| 2025 | Dec 31, 2025 | 9.3× | +1.5 |
| 2024 | Dec 31, 2024 | 7.9× | +7.5 |
| 2023 | Dec 29, 2023 | 0.3× | −0.1 |
| 2022 | Dec 30, 2022 | 0.4× | +0.4 |
| 2021 | Jan 29, 2021 | 0.0× | +0.0 |
| 2020 | Dec 31, 2020 | 0.0× | – |
See a number that looks wrong?